4 May 2022
Coave Therapeutics to Present Data on its Chemically Engineered AAV Vectors for Gene Therapy in CNS Disease at ASCGT
Author: admintech | Filed under: Press ReleasePARIS, May 4, 2022 /PRNewswire/ — Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announced that research on its AAV-Ligand Conjugates platform (ALIGATER) will…